...Histologically confirmed diagnosis of HER-2 negative (i.e. no gene amplification by FISH or IHC 2+ and no amplification by FISH or IHC 0/1+) infiltrating primary breast cancer. ...

...- Primary tumor was HER-2 negative (IHC 0 or IHC 1+/2+ and Fluorescence in situ hybridization [FISH] ≤ 1.9)...

...- Female patients at least 18 years old with HER-2 negative breast cancer....

...All patients will be erbB2 negative.-Patients must have measurable breast cancer, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10mm with ultrasound.-No prior chemotherapy for breast cancer if given less than two years ago.- Age > or = to 18 years.- Life expectancy of greater than 12 weeks--ECOG performance status 2- Patients must have normal organ and marrow function as defined in the protocol.- Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram.- Eligibility of patients receiving medications or substances known to affect, or with the potential to affect the activity or pharmacokinetics of Lapatinib will be determined following review of their use by the Principal Investigator.- Women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation.- Able to give written informed consent.- Able to swallow and retain oral medication....

...- Tumor must be HER-2 negative, and estrogen and progesterone receptors negative....

Median PFS was significantly longer in A+CT than in CT (182 days vs 63 days; P = 0.043);The median PFS of TNBC subgroup (11 in A+CT group, 14 in CT) was longer in the aptinib group than in CT group (167 days vs 63 days; P = 0.637);The median PFS of HR+ subgroup(25 in apatinib group, 20 in chemotherapy group) was longer in the aptinib group than in CT group (259 days vs 56 days; P = 0.054);The median PFS of patients with liver metastases(19 in apatinib group, 17 in chemotherapy group) was longer in the aptinib group than in the CT group (151 days vs 54 days; P = 0.191)...Apatinib combined with chemotherapy showed a significant improvements in PFS and a manageable safety profile in HER2 negative MBC.

Apatinib combined with etoposide capsules is effective and tolerable in heavily pretreated, metastatic HER2-negative breast cancer patient.

This single arm prospective study enrolled patients with HER2 negative advanced breast cancer...Patients were treated with apatinib 500/425 mg daily plus oral vinorelbine 60-80 mg/m2 day1,8,15, q3W….Of all 40 patients, median PFS was 5.2 months (95% CI, 3.7-6.7). 31 patients were eligible for efficacy analysis. ORR was 16.1% (5/31). CBR was 38.7% (12/31)....The all-oral therapy of apatinib plus vinorelbine presented objective efficacy in heavily pretreated advanced HER2-negative breast cancer...